Vicore Pharma completes enrolment of the global Phase 2b ASPIRE trial evaluating buloxibutid in idiopathic pulmonary fibrosis with topline results are expected in mid-2027 - Meet them in September

Calluna Pharma completes enrolment six months ahead of schedule for its global Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis with topline results are expected in Q1 2027

Understanding the Biological Drivers of IPF for Novel Targets with Therapeutic Benefit

11:29 am - Wednesday 30th September 2026

Understanding the Biological Drivers of IPF for Novel Targets with Therapeutic Benefit

Understanding the Biological Drivers of IPF for Novel Targets with Therapeutic Benefit

Venue

Map

Contact

Join Our Team

About Us

Explore Our Conferences

Stay Connected

Search

Organized By